Drug class
Norepinephrine–dopamine–serotonin reuptake inhibitor (NDSRI); central nervous system stimulant
Mechanism of action
Inhibits the norepinephrine, dopamine and serotonin reuptake transporters. The mechanism by which centanafadine produces clinical benefit in ADHD is not fully established, but its efficacy may be mediated by increased availability of these monoamine neurotransmitters.
General use cases
- Treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and paediatric patients aged 6 years and older weighing at least 20 kg under the US FDA SIMTRIYO indication (approved 24 July 2026); not recommended in children under 6 years or weighing less than 20 kg
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
